Browsing The Christie Research Publications Repository by Authors
Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp TrialSandhu, S; Mateo, J; Miranda, S; Carreira, S; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, Tony; et al. (2015)
DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancerMateo, J; Sandhu, S; Miranda, S; Carreira, S; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, Tony; et al. (2015-08-02)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; et al. (2015-10-29)Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.